Ana Teixeira-Marques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Teixeira-Marques has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Rui Henrique
Portuguese Oncology Institute of Porto (IPO Porto)
3 shared publications - Carmen Jerónimo
Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (P.CCC)
2 shared publications A.C.A. Roque
Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, Portugal
1 shared publication- António César Silva Ferreira
Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4200-072 Porto, Portugal
1 shared publication C. Jerónimo
Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal; Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
1 shared publication- Catarina Lourenço
I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 4 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6757
Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
Bladder cancer (BC) is the 10th most frequently diagnosed cancer worldwide. Although urine cytology and cystoscopy are current standards for BC diagnosis, both have limited sensitivity to detect low-grade and small tumors. Moreover, effective prognostic biomarkers are lacking. Extracellular vesicles (EVs) are lipidic particles that contain nucleic acids, proteins, and metabolites, which are released by cells into the extracellular space, being crucial effectors in intercellular communication. These particles have emerged as potential tools carrying biomarkers for either diagnosis or prognosis in liquid biopsies namely urine, plasma, and serum. Herein, we review the potential of liquid biopsies EVs’ cargo as BC diagnosis and prognosis biomarkers. Additionally, we address the emerging advantages and downsides of using EVs within this framework.
- 4 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6757
Open AccessExtracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
Bladder cancer (BC) is the 10th most frequently diagnosed cancer worldwide. Although urine cytology and cystoscopy are current standards for BC diagnosis, both have limited sensitivity to detect low-grade and small tumors. Moreover, effective prognostic biomarkers are lacking. Extracellular vesicles (EVs) are lipidic particles that contain nucleic acids, proteins, and metabolites, which are released by cells into the extracellular space, being crucial effectors in intercellular communication. These particles have emerged as potential tools carrying biomarkers for either diagnosis or prognosis in liquid biopsies namely urine, plasma, and serum. Herein, we review the potential of liquid biopsies EVs’ cargo as BC diagnosis and prognosis biomarkers. Additionally, we address the emerging advantages and downsides of using EVs within this framework.
- 7 October 2021
- Published by Taylor & Francis in Epigenomics
- Vol. 13 (19) , 1514-1521
Epigenetic extracellular vesicle-based biomarkers for urological malignancies: is the hope worth the hype?
- 7 October 2021
- Published by Taylor & Francis in Epigenomics
- Vol. 13 (19) , 1514-1521
Epigenetic extracellular vesicle-based biomarkers for urological malignancies: is the hope worth the hype?